Established in 2011, Blockade Medical has experience of more than 65 years in the neurovascular field and specialises in the development of catheter based therapeutic devices for the treatment of cerebral aneurysms.
The transaction is aligned with Balt’s strategy of emerging as a global leader in the neurovascular field, as well as increasing its footprint in the US.
BALT International president and BALT CEO Pascal Girin said: “This acquisition is a first strategic move towards transforming BALT into an integrated global neurovascular device company.
“BALT is recognised as a first mover in the market thanks to a world-class R&D team, which has proven its ability and rapidity to develop blockbuster products such as the LEO stent, the SILK flow diverter and the SONIC detachable tip micro catheter.
“Blockade will nicely complement our product portfolio and will give us a strong expandable US based platform for our future development.”
The transaction has enhanced BALT’s product portfolio with the addition of Blockade’s Barricade Coil System.
The Barricade Coil System is a range of platinum coils varying in sizes to frame, fill and finish aneurysms with reduced shelf space requirements.
The coils feature a short, flexible detachment zone to facilitate faster detachment times and minimal microcatheter recoil.
The company will also develop and commercialise additional neurovascular devices for the treatment of aneurysms, stroke and other neurovascular conditions.